Notable Biotech Gainers | RXi Pharmaceuticals (RXII) | Prima Biomed (PBMD) | Amedisys (AMED) | Vical Incorporated (VICL)

0

Looking in the biotech market today, we’re seeing a sea of red. However, even on the bad days, we tend to see notable gainers. With that said, here are some of the fastest moving gainers in biotech today…

RXi Pharmaceuticals Stock Climbs On Notices Of Allowance

RXi Pharmaceuticals Corp (NASDAQ: RXII)

RXII is having a great day in the market today regardless of the biotech sea of red. The company announced that they have received two Notices of Allowance from the United States Patent and Trademark Office. As a result, the stock is continuing its bullish run, even on the bad day today. So, it may be a good idea to start looking for pull backs as this one is likely to keep heading toward the top.

Prima Biomed Stock Is Seeing Gains

Prima Biomed Sp ADR (NASDAQ: PBMD)

Prima Biomed has been a hot topic in the world of financial social media recently; and today, it seems to be looking for a breakout. Earlier in trading today, the stock climbed by more than 3% from yesterday’s close. However, a pull back has started; ultimately bringing those gains down. Currently (12:58), PBMD is trading at $2.22 per share after a gain of 1.37%; however, I’m expecting to see a strong close from the stock today. So, watch this one closely for more opportunities.

Amedisys Stock Climbs On Deutsche Bank Upgrade

Amedisys Inc (NASDAQ: AMED)

AMED is having a great day in the market today following news that broke early this morning. Deutsche Bank has upgraded the stock to a buy from a hold. Perhaps more importantly, they have increased their price target on the stock from $28 to $41; insinuating incredible upside potential. As a result, we’ve seen a relatively strong day in the market for the stock; and I don’t think we’re going to see a change in momentum anytime soon. So, look for pull backs and entrance opportunities for your chance to partake in the gains.

Vical Incorporated Stock Climbs On Roth Capital Buy Reiteration

Vical Incorporated (NASDAQ: VICL)

Finally, Vical Incorporated stock is having a strong day in the market as well. Yesterday Roth Capital reiterated their views with regard to the stock; repeating a “Buy” rating with a target price of $4.65. As a result, the stock is having a strong day in the market today; and will most likely keep the uptrends rolling for some time to come. So, this is another one to start looking for pull backs in for great buying opportunities.

Do You Know Of Any Other Biotech Gainers Today?

If so, let us know in the comments below!

LEAVE A REPLY

Please enter your comment!
Please enter your name here